Shionogi expands allergy interests with nucleic acid therapy deal
This article was originally published in Scrip
Shionogi has added to its existing limited presence in the allergy area with the acquisition of exclusive global rights to AnGes MG's pipeline nuclear factor-kappa B decoy oligodeoxynucleotide therapy for the treatment of atopic dermatitis and other skin disorders.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.